GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Artivion Inc (NYSE:AORT) » Definitions » ROE %

Artivion (Artivion) ROE % : -5.74% (As of Dec. 2023)


View and export this data going back to 1993. Start your Free Trial

What is Artivion ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Artivion's annualized net income for the quarter that ended in Dec. 2023 was $-15.9 Mil. Artivion's average Total Stockholders Equity over the quarter that ended in Dec. 2023 was $276.9 Mil. Therefore, Artivion's annualized ROE % for the quarter that ended in Dec. 2023 was -5.74%.

The historical rank and industry rank for Artivion's ROE % or its related term are showing as below:

AORT' s ROE % Range Over the Past 10 Years
Min: -10.96   Med: -0.21   Max: 5.92
Current: -10.96

During the past 13 years, Artivion's highest ROE % was 5.92%. The lowest was -10.96%. And the median was -0.21%.

AORT's ROE % is ranked worse than
59.46% of 809 companies
in the Medical Devices & Instruments industry
Industry Median: 0.25 vs AORT: -10.96

Artivion ROE % Historical Data

The historical data trend for Artivion's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Artivion ROE % Chart

Artivion Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.61 -5.43 -4.71 -6.56 -10.84

Artivion Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.22 -19.19 -4.81 -14.14 -5.74

Competitive Comparison of Artivion's ROE %

For the Medical Devices subindustry, Artivion's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Artivion's ROE % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Artivion's ROE % distribution charts can be found below:

* The bar in red indicates where Artivion's ROE % falls into.



Artivion ROE % Calculation

Artivion's annualized ROE % for the fiscal year that ended in Dec. 2023 is calculated as

ROE %=Net Income (A: Dec. 2023 )/( (Total Stockholders Equity (A: Dec. 2022 )+Total Stockholders Equity (A: Dec. 2023 ))/ count )
=-30.69/( (284.329+281.78)/ 2 )
=-30.69/283.0545
=-10.84 %

Artivion's annualized ROE % for the quarter that ended in Dec. 2023 is calculated as

ROE %=Net Income (Q: Dec. 2023 )/( (Total Stockholders Equity (Q: Sep. 2023 )+Total Stockholders Equity (Q: Dec. 2023 ))/ count )
=-15.9/( (271.975+281.78)/ 2 )
=-15.9/276.8775
=-5.74 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Dec. 2023) net income data. ROE % is displayed in the 30-year financial page.


Artivion  (NYSE:AORT) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-15.9/276.8775
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-15.9 / 374.68)*(374.68 / 783.592)*(783.592 / 276.8775)
=Net Margin %*Asset Turnover*Equity Multiplier
=-4.24 %*0.4782*2.8301
=ROA %*Equity Multiplier
=-2.03 %*2.8301
=-5.74 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-15.9/276.8775
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-15.9 / -2.364) * (-2.364 / 12.688) * (12.688 / 374.68) * (374.68 / 783.592) * (783.592 / 276.8775)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 6.7259 * -0.1863 * 3.39 % * 0.4782 * 2.8301
=-5.74 %

Note: The net income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Artivion ROE % Related Terms

Thank you for viewing the detailed overview of Artivion's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Artivion (Artivion) Business Description

Traded in Other Exchanges
Address
1655 Roberts Boulevard North West, Kennesaw, GA, USA, 30144
Artivion Inc offers cardiac and vascular surgeons a suite of aortic-centric solutions. The company's products include Aortic Heart Valve, Mitral Heart Valve, Aortic Allograft, Pulmonary Human Heart Valve, Pulmonary Patch, and Surgical Adhesive among others.
Executives
Jean F Holloway officer: VP, General Counsel C/O ARTIVION INC, 1655 ROBERTS BLVD, KENNESAW GA 30144
John E Davis officer: Senior VP, Global Sales 1655 ROBERTS BLVD., NW, KENNESAW GA 30144
Amy Horton officer: Chief Accounting Officer C/O CRYOLIFE, INC., 1655 ROBERTS BLVD., NW, KENNESAW GA 30144
Florian Tyrs officer: VP, Global Operations IM SOELLER 3, BALINGEN 2M 72336
Robert C Thomson officer: VP Research & Development 33 HABERSHAM COVE DRIVE, NW, ATLANTA GA 30305
Matthew A Getz officer: VP, Human Resources 1655 ROBERTS BLVD NW, KENNESAW GA 30144
Dennis B Maier officer: Vice President, Operations 1655 ROBERTS BLVD, NW, KENNESAW GA 30144
Rochelle L. Maney officer: VP, Quality 1655 ROBERTS BLVD, NW, KENNESAW GA 30144
James P Mackin officer: President & CEO ARTIVION, INC., 1655 ROBERTS BLVD, NW, KENNESAW GA 30144
Marshall S. Stanton officer: SVP, Clinical & MD Affair 1655 ROBERTS BLVD, NW, KENNESAW GA 30144
Andrew M Green officer: VP Regulatory ARTIVION INC, 1655 ROBERTS BLVD, KENNESAW GA 30144
David Ashley Lee officer: Executive VP, COO & CFO C/O CRYOLIFE INC, 1655 ROBERTS BLVD NW, KENNESAW GA 30144
Elizabeth A Hoff director 2701 WESTHEIMER ROAD, UNIT 1-E, HOUSTON TX 77098
Anthony B. Semedo director 3288 HARRISON GRADE ROAD, SEBASTOPOL CA 95472
Ronald D Mccall director C/O CRYOLIFE, INC., 1655 ROBERTS BOULEVARD, NW, KENNESAW GA 30144